[
  {
    "ts": null,
    "headline": "Is Eli Lilly Stock a Buy Right Now?",
    "summary": "The pharmaceutical sector could be the next industry to face sweeping tariffs from the Trump administration.",
    "url": "https://finnhub.io/api/news?id=e17198bc01bba36ac58778909e38a2b7ce97ec3fe97aee6781de93f49ced3d33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745093100,
      "headline": "Is Eli Lilly Stock a Buy Right Now?",
      "id": 134022707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharmaceutical sector could be the next industry to face sweeping tariffs from the Trump administration.",
      "url": "https://finnhub.io/api/news?id=e17198bc01bba36ac58778909e38a2b7ce97ec3fe97aee6781de93f49ced3d33"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (LLY) the Best Low Volatility Stock to Buy Now?",
    "summary": "We recently published a list of 10 Best Low Volatility Stocks to Buy Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low volatility stocks to buy now. The US stock market experienced a turbulent first quarter of 2025, marked by increased […]",
    "url": "https://finnhub.io/api/news?id=782ef276dcaaed31aa2344b93cc4b2f7b4886a021b46e237da6826705860a0b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745089784,
      "headline": "Is Eli Lilly and Company (LLY) the Best Low Volatility Stock to Buy Now?",
      "id": 134022708,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Low Volatility Stocks to Buy Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low volatility stocks to buy now. The US stock market experienced a turbulent first quarter of 2025, marked by increased […]",
      "url": "https://finnhub.io/api/news?id=782ef276dcaaed31aa2344b93cc4b2f7b4886a021b46e237da6826705860a0b2"
    }
  },
  {
    "ts": null,
    "headline": "What Moved Markets This Week",
    "summary": "What Moved Markets This Week",
    "url": "https://finnhub.io/api/news?id=08c44b8ae67341e26dd2423b7c1a73e23d1bf8f72ed4602deb28cdbabca685b9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745048680,
      "headline": "What Moved Markets This Week",
      "id": 133971140,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=08c44b8ae67341e26dd2423b7c1a73e23d1bf8f72ed4602deb28cdbabca685b9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?",
    "summary": "More than 2 out of 5 American adults are obese, according to the Centers for Disease Control.  With this figure in mind, it's no wonder Wall Street investment banks are telling anyone who will listen that sales of anti-obesity drugs could soar.  Last year, Morgan Stanley said the global market for obesity drugs could increase more than 15-fold to reach $144 billion by 2030.",
    "url": "https://finnhub.io/api/news?id=bcb1281794d5d8397ddc6432a4542743da8324fca8663f8b07055708dba24be0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745047380,
      "headline": "Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?",
      "id": 133969836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "More than 2 out of 5 American adults are obese, according to the Centers for Disease Control.  With this figure in mind, it's no wonder Wall Street investment banks are telling anyone who will listen that sales of anti-obesity drugs could soar.  Last year, Morgan Stanley said the global market for obesity drugs could increase more than 15-fold to reach $144 billion by 2030.",
      "url": "https://finnhub.io/api/news?id=bcb1281794d5d8397ddc6432a4542743da8324fca8663f8b07055708dba24be0"
    }
  }
]